A Phase II Study of CRT Combined With QL1706 in ESCC Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 30, 2025

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

QL1706

QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.

Trial Locations (1)

RECRUITING

Tianjin cancer hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER